60 Degrees Pharmaceuticals Announces Date for Hospitalized Babesiosis Study Interim Data Release and Key Opinion Leader Webinar

60 Degrees Pharmaceuticals (SXTP) will release interim results from its hospitalized babesiosis study and host an investor webinar on October 6, 2026.

Rhea-AI Summary

60 Degrees Pharmaceuticals (SXTP) will release interim results from its hospitalized babesiosis study and host an investor webinar on October 6, 2026.

The study, NCT06207370, evaluates tafenoquine in patients hospitalized with severe babesiosis. The webinar begins at 11:00 a.m. ET and features Dr. Peter Krause and Dr. Edouard Vannier. It will review clinical data from the company's hospital and expanded access studies, alongside published literature, and discuss tafenoquine's potential role in recurrent tick-borne infections. A live question-and-answer session will follow. Tafenoquine is approved in the United States for malaria prevention as ARAKODA, but not for treating or preventing babesiosis.

Argus 15 min delay 3 alerts

-3.76% vs previous close $1.28 last price 3.5x rel. volume Open Argus

Details

Market move: SXTP -3.76% vs previous close. babesiosis interim data release

$1.24 – $1.39 Day Range

$4.50M Market Cap

On Oct 1, the day this news came out, the latest delayed price for SXTP is 3.76% below the previous close. Our momentum scanner has recorded 3 alerts for this stock so far that day. The latest delayed price is $1.28. Relative volume is very high at 3.5x the average.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.

Key Figures

Interim data release date: October 6, 2026

Interim data release date

October 6, 2026

Interim analysis of tafenoquine in severe babesiosis

Historical Context

1 past event · Latest: Jul 29

1 event

1. Jul 29

   Minimum enrollment

   24h Move

   -16.1%

   Reached the 24-patient minimum triggering interim analysis in the same hospitalized babesiosis trial.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

interim analysis, standard-of-care, malaria prophylaxis

3 terms

interim analysis medical

"Interim analysis results from clinical study evaluating tafenoquine"

An interim analysis is an early review of a project or process before it is fully completed. For investors, it provides a snapshot of progress or performance, helping to identify whether things are on track, need adjustment, or should be stopped early. Think of it as a progress report that can influence decisions before the final outcome is known.

standard-of-care medical

"establishing atovaquone/azithromycin as standard-of-care"

The standard-of-care is the widely accepted medical treatment or procedure that doctors typically use for a particular illness, based on current evidence and clinical practice. For investors it matters because new drugs or devices must beat or match this baseline to be adopted, reimbursed and widely sold—think of it as the default recipe a market expects; a new product must prove it’s tastier, cheaper, or faster to replace it.

malaria prophylaxis medical

"approved for malaria prophylaxis in the United States"

Malaria prophylaxis is the use of medications or preventive measures to stop malaria infection before or during exposure, similar to carrying an umbrella to avoid getting wet in a storm. For investors, prophylaxis matters because it drives demand for drugs, influences regulatory review and approval pathways, affects manufacturing and supply chains, and shapes market size and revenue forecasts for companies developing or selling preventive treatments.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

• Interim analysis results from clinical study evaluating tafenoquine in severe babesiosis (NCT06207370) to be disclosed on October 6, 2026.
• Key Opinion Leader investor webinar scheduled for October 6, 2026, featuring leading babesiosis experts Dr. Peter Krause and Dr. Edouard Vannier.

WASHINGTON, Oct. 01, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) ("60 Degrees" or the "Company"), a pharmaceutical company that develops and commercializes new medicines for vector-borne disease, today announced that it will disclose the outcome of the interim analysis from its clinical study evaluating tafenoquine in patients hospitalized with severe babesiosis (NCT06207370) on October 6, 2026.

In conjunction with the data release, 60 Degrees will host a Key Opinion Leader (KOL) investor webinar on Tuesday, October 6, 2026. The webinar will highlight the substantial unmet medical need for new therapeutic options in relapsing and treatment-refractory babesiosis, review the clinical data from Company’s hospital and expanded access studies and the literature, and discuss the potential role of tafenoquine in addressing recurrent tick-borne infections.

Webinar Featured Speakers

• Peter J. Krause, M.D., Senior Research Scientist in the Department of Epidemiology and Public Health at Yale School of Public Health and Yale School of Medicine. Dr. Krause is an internationally recognized authority on human babesiosis who led the original antibiotic treatment trial establishing atovaquone/azithromycin as standard-of-care 25 years ago.
• Edouard Vannier, Ph.D., Assistant Professor of Medicine at Tufts Medical Center / Tufts University School of Medicine, a leading clinical researcher specializing in the pathogenesis, diagnosis, and treatment of Babesia microti infection.

During the presentation, the speakers will address the clinical burden of persistent babesiosis in immunocompromised hosts, treatment limitations under current guidelines, and the mechanistic rationale for tafenoquine combination therapy. A live question-and-answer session will follow the presentation.

No FDA-approved treatment or vaccine exists for babesiosis. Tafenoquine is not currently approved by the FDA for the treatment and prevention of babesiosis. Tafenoquine is approved for malaria prophylaxis in the United States under the product name ARAKODA® (tafenoquine).

Webinar Details

• Date: Tuesday, October 6, 2026
• Time: 11:00 a.m. ET
• Registration / Webcast Link
  
  

About 60 Degrees Pharmaceuticals, Inc.

60 Degrees Pharmaceuticals, Inc., founded in 2010, develops and commercializes new medicines for the treatment and prevention of vector-borne disease. The Company achieved U.S. Food and Drug Administration approval of its lead product, ARAKODA® (tafenoquine), for malaria prevention in 2018 and currently has active clinical trials underway for babesiosis, an emerging tick-borne disease. ARAKODA is sold commercially in the U.S. and Australia. 60 Degrees also collaborates with prominent research and academic organizations in the U.S. and Australia to advance science around vector-borne disease. The Company is headquartered in Washington, D.C., with a subsidiary in Australia. Learn more at www.60degreespharma.com.

Cautionary Note Regarding Forward-Looking Statements
This press release may contain “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward‐looking statements reflect the current view about future events. When used in this press release, the words “anticipate,” “believe,” “estimate,” “expect,” “future,” “intend,” “plan,” or the negative of these terms and similar expressions, as they relate to us or our management, identify forward‐looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy, activities of regulators and future regulations and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: there is substantial doubt as to our ability to continue on a going-concern basis; we might not be eligible for Australian government research and development tax rebates; if we are not able to successfully develop, obtain FDA approval for, and provide for the commercialization of non-malaria prevention indications for tafenoquine (ARAKODA® or other regimen) or Celgosivir in a timely manner, we may not be able to expand our business operations; we may not be able to successfully conduct planned clinical trials; and we have no manufacturing capacity which puts us at risk of lengthy and costly delays of bringing our products to market. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (“SEC”), including the information contained in our Annual Report on Form 10-K filed with the SEC on March 30, 2026, and our subsequent SEC filings. Investors and security holders are urged to read these documents free of charge on the SEC’s website at www.sec.gov. As a result of these matters, changes in facts, assumptions not being realized, or other circumstances, the Company’s actual results may differ materially from the expected results discussed in the forward-looking statements contained in this press release. Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Contacts

Media Contact:
Kristen Landon
kristenlandon@60degreespharma.com

Investor Contact:
Patrick Gaynes
patrickgaynes@60degreespharma.com